Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The central hypothesis of this study is that use of a less toxic chemotherapy preparative
regimen for allogeneic hematopoietic stem cell transplantation in combination with T cell
depletion with alemtuzumab for patients with high risk hematologic malignancies will allow
effective control of disease and improved disease free and overall survival compared with
historical expectations. Specifically, the objectives are to estimate toxicity, disease free,
progression free, event free, and overall survival rates in patients treated with alemtuzumab
T cell depleted, reduced intensity preparative regimen followed by allogeneic hematopoietic
transplantation; evaluate immune recovery following this reduced intensity allogeneic
immunotherapy; develop an in vitro assay to allow patient individualized targeted dosing.